Physician profile
Eric Franklin Grabowski
NPI 1285607481
$56,090.20
in general payments reported to CMS, 2019-2025
10 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,842 · 2021: $450 · 2022: $12K · 2023: $6,846 · 2024: $22K · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Travel and Lodging: $1,135 · Food and Beverage: $955 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $750 · Education: $92.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,120.00 |
| Travel and Lodging | $1,135.32 |
| Food and Beverage | $954.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $750.00 |
| Education | $92.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23,511.65 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $15,102.64 | 2024 | |
| Shire North American Group INC | $10,378.42 | 2019 | |
| Bioverativ Therapeutics INC. | $3,842.00 | 2020 | |
| Hema Biologics, LLC | $2,507.84 | 2022 | |
| Genentech, INC. | $449.55 | 2021 | |
| Csl Behring | $205.83 | 2019-2025 | Humate-P |
| Biomarin Pharmaceutical INC. | $60.00 | 2023 | |
| Novo Nordisk INC | $32.27 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Grabowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.